drugset / Trial / NCT00678106

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

NCT00678106

Phase 1 Completed 10 enrolled Pfizer
Non-randomizedSingle-groupOpen-label

Summary

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

Timeline

Start
2008-09
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalbavancin Other / unclassified 15 mg/kg Intravenous
Subject Dalbavancin Other / unclassified 1 g Intravenous